The PROSPECT-Lung trial (CTIU2317-A082304-S2402) is presented as a pragmatic clinical trial design intended to improve cancer trial efficiency without compromising scientific rigor. The trial focuses on patients with resectable non-small cell lung cancer and compares perioperative versus adjuvant systemic therapy.
The described approach emphasizes simplified eligibility criteria, a streamlined protocol, and reduced data-collection demands to address common sources of inefficiency in traditional trials, such as extensive data requirements, restrictive entry criteria, lengthy protocols, staffing shortages, and operational burden. By adopting pragmatic features, the design aims to facilitate faster accrual and lower operational costs while preserving methodological integrity.
The description positions PROSPECT-Lung as a potential model for aligning pragmatic trial elements with rigorous research standards in oncology. The source notes uncertainty regarding specific outcomes, statistical methodologies, or enrollment targets beyond the stated aims of efficiency and feasibility.
If more detailed results or formal comparative analyses are available, they are not provided in the quoted material.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 24 Feb 2026.
The item focuses on PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
Review the original article for the full source wording and details.